Osaka, Japan

Nobuo Cho

USPTO Granted Patents = 8 



Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 112(Granted Patents)


Location History:

  • Tsukuba, JP (2009 - 2012)
  • Osaka, JP (2007 - 2014)
  • Fujisawa, JP (2016)
  • Kanagawa, JP (2023)

Company Filing History:


Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: Nobuo Cho: Innovator in Cancer Therapeutics

Introduction

Nobuo Cho is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of cancer therapeutics, holding a total of 8 patents. His work focuses on developing innovative compounds that can potentially improve cancer treatment outcomes.

Latest Patents

Among his latest patents, Nobuo Cho has developed nitrogen-containing heterocycles as CDK12 inhibitors. These compounds are expected to exhibit superior CDK12 inhibitory action, making them promising candidates for use as prophylactic or therapeutic drugs for cancer and similar diseases. The compounds are represented by specific formulas, which detail their chemical structure and potential applications.

Career Highlights

Nobuo Cho has had a distinguished career, working with notable companies such as Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc. His experience in these organizations has allowed him to advance his research and contribute to the development of effective cancer therapies.

Collaborations

Throughout his career, Nobuo Cho has collaborated with esteemed colleagues, including Takashi Imada and Takenori Hitaka. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Nobuo Cho's innovative research and development of CDK12 inhibitors highlight his commitment to advancing cancer therapeutics. His contributions are expected to play a crucial role in improving treatment options for patients facing this challenging disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…